cf. Pennsylvania Vol.11 (corporations: CSL Behring) / Australia Vol.29
OUR COMPANY | Seqirus
Fluad In-Season | Seqirus US
Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market (07/30/2020) | multivu.com
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age. | @nlm_news
Seqirus Announces U.S. FDA Approval of Its First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine (02/03/2020) | @YahooFinance
First Adjuvanted Quadrivalent Influenza Vaccine by Seqirus Receives EU Approval (08/06/2020) | CISION
Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine (12/11/2019) | CISION
Seqirus Ships Northern Hemisphere Flu Vaccines (07/15/2019) | precision vaccinations
Human Vaccines Project and Seqirus partner to advance universal flu vaccine research (28/06/2018) | @EurekAlert
Joint media release from Invest Liverpool, the Mayor of Liverpool and Seqirus (25/02/2017) | Seqirus
CSL completes purchase of Novartis’ flu vaccine business (08/03/2015) | @FiercePharma
We’re honored to be ranked as one of the World’s Best Employers by @Forbes for 2020! Thank you to the entire @CSL team. We’re so proud of this achievement, and we wouldn't be here without all of you. #CSL #CSLBehring #CSLPlasma #Seqirus short.url/aBcXyZ pic.twitter.com/VvId46VOgI
— CSL (@CSL) October 29, 2020
Seqirus, part of CSL, has quadrupled cell-based #flu vaccine production and is proud to partner with the U.S. govt on pandemic preparedness. pic.twitter.com/cX3uc0qriG
— CSL Behring (@CSLBehring) August 8, 2017
Seqirus, part of CSL Limited, has distributed the first doses of #flu vaccine to US customers for the 17-18 season. https://t.co/HQF8PKVyKV pic.twitter.com/2WB4bKmOnJ
— CSL Behring (@CSLBehring) July 26, 2017
New £40 m Seqirus @CSL investment in Liverpool supporting @beisgovuk Industrial Strategy – making the UK the home of biomedical innovation & ensuring investment across the UK @GregClarkMP @MetroMayorSteve @lpoolcouncil @investliverpool
— Office for Life Sciences (@UK_Life_Science) November 13, 2017
Great to see the @CSL_Seqirus £40m investment in Liverpool City Region as a highlight 👍 UK trumpets life sciences sector deal @mattbiagetti @LCRLifeScience #pharma https://t.co/ZW0g1OVckW via @pmlivecom
— Invest Liverpool (@investliverpool) December 6, 2017
£40 million investment from Seqirus @CSL in their Liverpool site boosting jobs for the City Region https://t.co/Pn58IbeWiC pic.twitter.com/qnz09V2mLk
— LiverpoolLEP (@LiverpoolLEP) November 8, 2017
There's welcome news for people who have been turned away from having their flu shot. @georgiamain7 #7News pic.twitter.com/oR4SwM82oj
— 7NEWS Melbourne (@7NewsMelbourne) July 16, 2018
Flu shot: Seqirus presents absolute efficacy data on cell-based quadrivalent influenza vaccine https://t.co/PS3CUOK70Z
— Outbreak News Today (@bactiman63) October 29, 2020
"LMB reports that Immunize Canada received grants from Pfizer Canada, Merck Canada, GSK Canada, Seqirus Canada and Sanofi Pasteur outside the submitted work." #ConflictOfInterest https://t.co/LCNnrodSJn
— Vaccine Choice CA (@VaccineChoiceCA) October 26, 2020
Medical Developments $MVP is jumping 11% after confirming a new CEO in Brent MacGregor from Seqirus (part of $CSL) #ausbiz https://t.co/ZQE82MwAdb
— CommSec (@CommSec) October 14, 2020
.@CSL vaccine subsidiary Seqirus has signed a final agreement with the federal govt to supply 51 m doses of a Uni of Queensland-CSL vaccine should the drug be proven effective and safe in clinical trials.@UQ_News https://t.co/8KwxY4p7BF #auspol #covidnews #COVID19 #manufacturing
— AustralianManufacturingForum (@AuManufacturing) October 8, 2020
Wonderful news! Two new #COVID-19 vaccine candidates developed by @MIPS_Australia @MonashPharm and @TheDohertyInst with @CSL-Seqirus have been awarded $3 million Medical Research Future Fund #MRFF. @ColinPoutonhttps://t.co/uv1QfwHvoD
— Marc Parlange (@ProvostParlange) September 21, 2020
A shot in the arm for a #COVID19 vaccine: The Commonwealth Government’s Medical Research Future Fund's invested almost $3 million into vaccine candidates developed by researchers from the @TheDohertyInst, @MIPS_Australia and @CSL-Seqirus. Read More: https://t.co/sKaOUGVfYM
— Monash University (@MonashUni) September 20, 2020
Real-world study touts #Seqirus cell-based #quadrivalent #influenza #vaccine #QIVc vs similar egg-based vaccine
Better prevents #flu-related or all-cause #hospitalizations, lower all-cause healthcare utilization costshttps://t.co/G2bkfU0jSE#InfectiousDiseases #immunization pic.twitter.com/HPNZt10cfn
— DDNews Online (@DDNewsOnline) September 16, 2020
.@DOST_PCHRD says these are the firms which signed the Confidentiality Disclosure Agreement with the Philippines for COVID-19 vaccines:
• Seqirus (Australia)
• Sinopharm (China)
• Sinovac (China)
• Gamaleya (Russia)
• Adimmune (Taiwan)— CNN Philippines (@cnnphilippines) September 11, 2020
Sanofi, Seqirus and GSK are the three biggest companies in the markethttps://t.co/rbAB3TIk50
— Mint (@livemint) August 16, 2020
Seqirus could supply up to 60 million doses of influenza vaccine to the U.S. market this year. Flu shot more important because of COVID-19. https://t.co/66bxzodTqp @CDCgov #seqirus #flu #influenza #fluvaccine #vaccine
— InfectiousDiseaseSE (@IDSE_Online) August 8, 2020
Drugmakers are ramping up to meet the demand. Australian vaccine maker CSL Ltd's Seqirus said demand from customers has increased by 10 percent. British-based GlaxoSmithKline said it is ready to increase manufacturing as needed. https://t.co/7ATgkx3iXk
— bdnews24.com (@bdnews24com) May 27, 2020
.@US_FDA has approved Audenz, an adjuvanted influenza A H5N1 monovalent vaccine. The approval was granted to Seqirus. https://t.co/8tG5Bfn0q2
— Contagion (@Contagion_Live) February 3, 2020
Glenmark said that it has received approval from Australian regulator to commercialise Ryaltris in Australia through its partner Seqirus.https://t.co/7ztfdpwwoV
— BloombergQuint (@BloombergQuint) December 20, 2019
Get #Vaccinated: Seqirus #Flu #Vaccine Reduces Hospitalization in Retirement Home Patients, Study Shows https://t.co/u7MajJC1Jk pic.twitter.com/kEljiC3bit
— I Am Biotech (@IAmBiotech) December 13, 2019
Big success for CSL’s Seqirus flu vaccines unit and the Holly Springs plant seems to be knocking me dead: @CSL says cell-based flu vaccines gave 36pc more protection https://t.co/wcZFR7SL6x
— Ben Potter (@OBenPotter) December 4, 2018
After early budget woes, flu-shot expert Seqirus swings to its first-ever profit https://t.co/arJafYIgfE #Seqirus # CSL Behring #Novartis #Influenza
— Haybury (@Hayburysearch) August 30, 2018
Great work from the @TheDohertyInst @AlfredHealth @TheRMH @GarvanInstitute @Sydney_Uni @CSL_Seqirus @StVincentsMelb @UniMelbMDHS flu experts led by the wonderful Professor Katherine Kadzierska https://t.co/CK2vCyxHmW
— Sharon Lewin (@ProfSharonLewin) February 15, 2018
Needle phobia? Here are some ways to overcome your fear of shots | N&O @Seqirus @CSL_Seqirus #pharmajet https://t.co/uvdGSqvjGD
— John Murawski (@johnmurawski) October 4, 2017
Seqirus @CSL flu vaccine made in Liverpool approved for UK https://t.co/X2PwFbOUrh #Liverpool– world-leading infectious diseases R&D &prod'n
— LCRLifeScience (@LCRLifeScience) August 23, 2017
An extra 2 million flu vaccines on the way, as CSL’s Seqirus’s returns to production as doctors, clinics and pharmacists exhaust supply – https://t.co/A3SIgcOLxB via @aus_business @australian #ausbiz #auspol #coronavirus #covid19australia #covid19
— Jared Lynch (@jaredm_lynch) April 19, 2020
CSL’s Seqirus first to bring this year’s flu vaccine to market, with stock already available at some pharmacies – https://t.co/QUxfcoXMj1 via @australian @aus_business #ausbiz #business #businessnews #finance #asx #fluvaccine #coronavirus #Covid_19
— Jared Lynch (@jaredm_lynch) March 4, 2020
Behring plasma business and Seqirus underpin CSL's FY18 results $CSL https://t.co/8K2ybwq3zs #ausbiz #XJO #investing #stocks #equities
— FNArena (@FNArena) August 16, 2018
CSL on the cusp of breaking even with its Seqirus vaccine $CSL https://t.co/hB7H3h7i8U #ausbiz #XJO #investing #stocks #equities
— FNArena (@FNArena) February 15, 2018
That's a wrap – what a fantastic #BioForum!
A massive thank you to our incredible speakers @ProfPaulYoung @UQ_News, Kanta Subbarao @WHOCCFluMelb @TheDohertyInst, David Glover @CSLBehring, Frank Albano @CSL Seqirus and facilitator Trent Munro @UQ_News 👏 https://t.co/o3yc4hTXkk
— BioMelbourne Network (@biomelb) June 26, 2020
Made in #Melbourne! Flu vaccines to protect Australians against seasonal flu manufactured by Seqirus @CSL to meet high demands! https://t.co/83sIcfxInQ
— BioMelbourne Network (@biomelb) May 28, 2018
Thank you to our #ruralrefresher20 sponsors @ACRRM, @MundipharmaTalk, @blackdoginst, @GenesisCare,
@akubraofficial1 @OUTBACKmagazine Medical Indemnity Protection Society, General Practice Mental Health Standards Collaboration, @RDNNSW, Link, Macquarie Medical Systems & Seqirus pic.twitter.com/mUkhiv2DlM— NSW RDN (@NSWRDN) March 28, 2020
A special thanks to Jacqui @CSL_Seqirus for the fascinating exhibition of historical influenza memorabilia #FluSymposium pic.twitter.com/zluAR7bSBE
— NSW Health Pathology (@NSWHPathology) September 14, 2018
An incredible example of collaboration between @uniQLD @CEPIvaccines @CSLBehring @CSL_Seqirus to develop an Australian novel vaccine thank you Prof Trent Murrow for facilitating @biomelb for hosting! #clinicaltrials #COVID19au pic.twitter.com/ou62YJbvHJ
— CT:IQ (@CTImpactQuality) June 26, 2020
Fear not, #CoffeeLovers… There will be bottomless barista #coffee in the #HCILounge at #ASM19KL, courtesy of @MSD_Aus @MundipharmaTalk & @CSL_Seqirus 🙂 Don't forget your keep cup! #CoffeeAddictsOfTheASM pic.twitter.com/IXMaAWht55
— ANZCA (@ANZCA) April 24, 2019
The Federal Government has secured an additional 800,000 #influenza #vaccinations, on top of almost 10 million doses already released this #fluseason under the National #Immunisation Program, state programs & on the private market #pharmacy @CSL_Seqirus @CSL @CSLBehring @GSK pic.twitter.com/BQTV1mK7eF
— Pharmacy Daily (@pharmacydaily) May 28, 2018
Great £40 million investment from Seqirus @CSL in their Liverpool site boosting jobs https://t.co/l7E3RdQTOk
— Dept. Int.Trade Aust (@tradegovukAUS) November 8, 2017
Gordon Naylor, President of Seqirus says @CSL narrowed down to UK due to stable political policy #AusBio16 #BioFest16 #InnovationisGREAT pic.twitter.com/B31tyZ2OiT
— Dept. Int.Trade Aust (@tradegovukAUS) October 26, 2016
Big thanks to our:
❤️ Platinum Sponsors: @GSK, @pfizer, @sanofipasteur
😍 Gold Sponsors: @MSDInvents
🤩 Silver Sponsors: @biomerieux Diagnostics
🤗 General Supporters: Seqirus, A CSL Company
🤗 Exhibitors: @AdmaBiologics, @QuidelDX
🙏Thank you for making #ESPID2020 possible!🙏 pic.twitter.com/Im6y9xVH06— ESPIDSociety (@ESPIDsociety) October 22, 2020
#FF: Special thanks to funders who made 2020 #NFID #Influenza/Pneumococcal News Conference possible https://t.co/Qo1iVvpGw2 @Merck @GSKUS @sanofipasteur @AstraZenecaUS @genentech @Seqirus #FightFlu #PreventPneumo pic.twitter.com/IEhpwGSt0I
— NFID (@NFIDvaccines) October 9, 2020
Our @unitetheunion reps from Seqirus in Liverpool have set up food collection points on site and have been sending all donations to The Trussell Trust Foodbank in Liverpool 👏#UniteHeroes #HereForYou pic.twitter.com/xAxXGpJw8V
— Unite North West (@Unite_NorthWest) April 16, 2020
Congratulations Seqirus Inc. on the FDA approval of AUDENZ. #BIBrands
AUDENZ is a cell-based vaccine designed to protect against influenza A (H5N1) in the event of a pandemic for people aged 6 months or older.#drugnaming #branding #FDAapproval #influenza #vaccine #H5N1 pic.twitter.com/WLWFVqcVEz
— Brand Institute, Inc (@BrandInstitute) February 6, 2020
Lovely morning for our first Pharma Manufacturing conference today @partnership4LC in Speke. Thx to our sponsors @AllerganBio @CSL_Seqirus @Elanco @AstraZeneca for making it possible #northernpowerhouse #maufacturing pic.twitter.com/OLzJCNYaKS
— Bionow (@Bionow) May 23, 2018
And the winner is…Coree Forman from Seqirus @CSL!
Congratulations!! Hope you enjoy your bottle of champagne#GQAC17 #GXPeople pic.twitter.com/FayhP6bDNh— GxPeople (@GxPeople) November 3, 2017
Holly Springs is ground zero for innovation in the flu vaccine space. @CSL_Seqirus has created a more effective, cell-based flu vaccine which will be produced at their Holly Springs facility. Life science production? #TriangleDelivers. @ToHollySprings @RaleighWake
— Ashley Cagle (@asherrillcagle) November 16, 2018
Exciting morning at @CSL_Seqirus in @ToHollySprings as they announce a major expansion of their fill finish production. @SenatorBurr declares Holly Springs a great place for innovation! We agree! #TriangleDelivers @RaleighWake pic.twitter.com/9dyqmKktU2
— Ashley Cagle (@asherrillcagle) November 16, 2018
Fascinating story for @publicmediaNC Science @CSL_Seqirus vaccine plant @ToHollySprings. Only site in U.S. producing cell culture #flu vaccine. 40M doses/year. #flushot #vaccines pic.twitter.com/FsW9TVj1V7
— Frank Graff (@fgraff4) January 25, 2019
Panelists from Seqirus @AveXisInc @Merck @thermofisher @bluebirdbio talk about the skills needed to land a job with their companies, moderated by Brenda Summers @ncbio pic.twitter.com/lisg0kWz1V
— NCBiotech #NCLifeSciences (@ncbiotech) March 3, 2020
Rodney Lam, Head of Engineering at @Seqirus @CSLBehring, Holly Springs, tells BPD @ncbiotech meeting participants about the importance of #flu shots this year during the global #COVID19 pandemic, "a season like we've never seen." pic.twitter.com/Jmr91fmpyr
— NCBIO (@ncbio) October 8, 2020
Great discussion on leadership development @ncbio Biotech Manufacturers Forum. Thanks to presenters Vinay Khanna @Merck Darren Alfano @NovozymesNA and Jon Kegerise @Seqirus. pic.twitter.com/VE1wL2ZDIL
— NCBIO (@ncbio) March 5, 2020
Congrats to @ncbio member Seqirus, an @CSL company, on the expansion in Holly Springs. https://t.co/ANzGbMdlTm
— NCBIO (@ncbio) December 7, 2017
Sam Taylor, @NCCommerce John Skvarla, @CSL_Seqirus John Anderson, and Doug Edgeton at #VaccinationNCCelebration @ncbiotech pic.twitter.com/5eUXGo7SPO
— NCBIO (@ncbio) October 4, 2016
Nearly three-quarters (73 per cent) of Canadians support having flu shots available in workplaces, finds a survey by pharmaceutical company Seqirus. https://t.co/hmBaIaLoNZ
— Canadian HR Reporter (@HRReporter) October 2, 2020
EOIs are now open for the 2021 cohort of our CSL Australia Graduate program with opportunities available within our CSL Behring & Seqirus businesses. Hear participants in the graduate program describe their experience https://t.co/9vWXe1IZHx #CSLgraduateprogram #promisingfutures pic.twitter.com/W0izJkb8fL
— CSL (@CSL) May 25, 2020
As workers are being laid off, we're proud to learn five #WakeTech Biopharma Tech grads have been hired by vaccine manufacturer Seqirus in Holly Springs!
Their roles are more important than ever, ensuring Seqirus can deliver the flu vaccine to the global market without issue. pic.twitter.com/zucN4mZIZy
— Wake Tech (@waketechcc) April 13, 2020